Biguanides Metformin |
Inhibits hepatic gluconeogenesis; increases insulin sensitivity. |
First-line T2DM; PCOS. |
GI upset, B12 deficiency. Boxed Warning: Lactic Acidosis. |
Contraindicated: eGFR < 30. Tip: "Meta-formin" -> Metallic taste. |
GLP-1 Agonists Semaglutide, Liraglutide, Dulaglutide, Exenatide |
Mimics GLP-1: Stimulates insulin, inhibits glucagon, slows gastric emptying. |
T2DM, Weight Loss, CV risk reduction. |
Nausea/Vomiting, Pancreatitis risk. |
Boxed Warning: Thyroid C-cell tumors (MEN2). Contraindicated: Hx of Medullary Thyroid Cancer. |
Dual Agonists Tirzepatide |
Agonist at GLP-1 and GIP receptors. |
T2DM, Weight Loss. |
GI effects similar to GLP-1s. |
"Twin-cretin". Targets 2 receptors. |
SGLT2 Inhibitors Empagliflozin, Dapagliflozin, Canagliflozin |
Inhibits SGLT2 in kidney; blocks glucose reabsorption. |
T2DM, Heart Failure, CKD. |
UTIs, Yeast infections, Osmotic diuresis, Euglycemic DKA. Fournier's Gangrene. |
Tip: "Flowing" urine. Warning: DKA with normal blood sugar. |
Amylin Analogs Pramlintide |
Mimics amylin: slows gastric emptying, suppresses glucagon. |
T1DM and T2DM adjunct. |
Severe hypoglycemia (with insulin), nausea. |
Warning: Reduce mealtime insulin by 50% when starting. |
Lipase Inhibitors Orlistat |
Inhibits lipases; blocks fat absorption. |
Long-term Weight Management. |
Steatorrhea, fecal urgency, Vit A,D,E,K deficiency. |
Warning: Bleeding risk (Vit K deficiency). |
Sympathomimetics Phentermine |
Stimulates norepinephrine release. |
Short-term Weight Loss. |
Tachycardia, HTN, Insomnia. Abuse potential. |
Contraindicated: CVD, Uncontrolled HTN, Hyperthyroidism. |
Combinations Qsymia, Contrave |
Qsymia: NE release + GABA mod. Contrave: Opioid antag + DA/NE reuptake. |
Chronic Weight Management. |
Qsymia: Paresthesia, Teratogenic. Contrave: Seizure risk (Bupropion). |
Contrave: CI in Seizure disorder / Opioid use. Qsymia: Pregnancy Category X. |